Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GNMK GenMark Diagnostics (GNMK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get GenMark Diagnostics alerts: Email Address About GenMark Diagnostics Stock (NASDAQ:GNMK) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWar on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?Watch my new exposé and find out. Get GenMark Diagnostics alerts:Sign Up Key Stats Today's Range$24.04▼$24.0450-Day Range$23.89▼$24.0452-Week Range$8.42▼$24.25VolumeN/AAverage Volume2.70 million shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.Read More… War on Elon Escalates… (Ad)One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows this. That’s why in his recent interview with Trump, he brought up this technology as a viable solution to America’s growing energy needs. What is this technology and why has it put Elon in the middle of an ideological war with the elites?Watch my new exposé and find out. Receive GNMK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GenMark Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMK Stock News HeadlinesQuest Diagnostics Incorporated (DGX)March 15, 2024 | finance.yahoo.comYouTube star Grace Helbig shares breast cancer diagnosisJuly 8, 2023 | nbcnews.comThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's right. You can grab shares of this potential retirement-maker for less than you'd pay for lunch.September 22, 2024 | Behind the Markets (Ad)Study finds brain 'signature' for chronic pain, which could improve diagnosis, treatmentJune 6, 2023 | usatoday.comGenmark Diagnos Share ChatJune 2, 2023 | lse.co.ukWhen autism isn't diagnosed until adulthood: 'It takes a mental crisis to get diagnosed'May 28, 2023 | usatoday.comDoctor who helped broaden autism spectrum ‘very sorry’ for over-diagnosisApril 29, 2023 | nypost.comWith 11.1% CAGR, Molecular Diagnostics Market to Surpass US$ 37.19 Bn by 2028 - Global Analysis by TMRApril 27, 2023 | benzinga.comSee More Headlines GNMK Stock Analysis - Frequently Asked Questions How were GenMark Diagnostics' earnings last quarter? GenMark Diagnostics, Inc. (NASDAQ:GNMK) released its earnings results on Thursday, February, 25th. The medical equipment provider reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by $0.04. The medical equipment provider earned $50.08 million during the quarter, compared to analysts' expectations of $50 million. GenMark Diagnostics had a negative net margin of 16.95% and a negative trailing twelve-month return on equity of 39.36%. What other stocks do shareholders of GenMark Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that GenMark Diagnostics investors own include Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS). Company Calendar Last Earnings2/25/2021Today9/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:GNMK CUSIPN/A CIK1487371 Webwww.genmarkdx.com Phone760-448-4300FaxN/AEmployees618Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,350,000.00 Net Margins-16.95% Pretax MarginN/A Return on Equity-39.36% Return on Assets-13.02% Debt Debt-to-Equity Ratio0.75 Current Ratio4.33 Quick Ratio3.84 Sales & Book Value Annual Sales$88.02 million Price / Sales19.96 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book114.48Miscellaneous Outstanding Shares73,086,000Free FloatN/AMarket Cap$1.76 billion OptionableOptionable Beta3.02 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:GNMK) was last updated on 9/22/2024 by MarketBeat.com Staff From Our PartnersJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GenMark Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GenMark Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.